HRP20200370T1 - Biokemijski stabilizirano hiv-1 trimer cjepivo - Google Patents
Biokemijski stabilizirano hiv-1 trimer cjepivo Download PDFInfo
- Publication number
- HRP20200370T1 HRP20200370T1 HRP20200370TT HRP20200370T HRP20200370T1 HR P20200370 T1 HRP20200370 T1 HR P20200370T1 HR P20200370T T HRP20200370T T HR P20200370TT HR P20200370 T HRP20200370 T HR P20200370T HR P20200370 T1 HRP20200370 T1 HR P20200370T1
- Authority
- HR
- Croatia
- Prior art keywords
- hiv
- trimer
- asn
- thr
- vaccine
- Prior art date
Links
- 239000013638 trimer Substances 0.000 title claims 21
- 229960005486 vaccine Drugs 0.000 title claims 8
- 241000725303 Human immunodeficiency virus Species 0.000 claims 26
- 108090000765 processed proteins & peptides Proteins 0.000 claims 10
- 150000001875 compounds Chemical class 0.000 claims 6
- 238000000034 method Methods 0.000 claims 6
- 102000004196 processed proteins & peptides Human genes 0.000 claims 6
- 229920001184 polypeptide Polymers 0.000 claims 5
- 230000003472 neutralizing effect Effects 0.000 claims 3
- 238000005829 trimerization reaction Methods 0.000 claims 3
- QIQABBIDHGQXGA-ZPFDUUQYSA-N Glu-Ile-Arg Chemical compound OC(=O)CC[C@H](N)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CCCN=C(N)N)C(O)=O QIQABBIDHGQXGA-ZPFDUUQYSA-N 0.000 claims 2
- XBWMTPAIUQIWKA-BYULHYEWSA-N Gly-Asp-Ile Chemical compound CC[C@H](C)[C@@H](C(O)=O)NC(=O)[C@H](CC(O)=O)NC(=O)CN XBWMTPAIUQIWKA-BYULHYEWSA-N 0.000 claims 2
- 241000713772 Human immunodeficiency virus 1 Species 0.000 claims 2
- 150000001413 amino acids Chemical group 0.000 claims 2
- 150000007523 nucleic acids Chemical group 0.000 claims 2
- FEZJJKXNPSEYEV-CIUDSAMLSA-N Arg-Gln-Ala Chemical compound [H]N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](C)C(O)=O FEZJJKXNPSEYEV-CIUDSAMLSA-N 0.000 claims 1
- NPAVRDPEFVKELR-DCAQKATOSA-N Arg-Lys-Ser Chemical compound [H]N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CO)C(O)=O NPAVRDPEFVKELR-DCAQKATOSA-N 0.000 claims 1
- OVQJAKFLFTZDNC-GUBZILKMSA-N Arg-Pro-Asp Chemical compound [H]N[C@@H](CCCNC(N)=N)C(=O)N1CCC[C@H]1C(=O)N[C@@H](CC(O)=O)C(O)=O OVQJAKFLFTZDNC-GUBZILKMSA-N 0.000 claims 1
- XHFXZQHTLJVZBN-FXQIFTODSA-N Asn-Arg-Asn Chemical compound C(C[C@@H](C(=O)N[C@@H](CC(=O)N)C(=O)O)NC(=O)[C@H](CC(=O)N)N)CN=C(N)N XHFXZQHTLJVZBN-FXQIFTODSA-N 0.000 claims 1
- QHBMKQWOIYJYMI-BYULHYEWSA-N Asn-Asn-Val Chemical compound [H]N[C@@H](CC(N)=O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](C(C)C)C(O)=O QHBMKQWOIYJYMI-BYULHYEWSA-N 0.000 claims 1
- SPIPSJXLZVTXJL-ZLUOBGJFSA-N Asn-Cys-Ser Chemical compound NC(=O)C[C@H](N)C(=O)N[C@@H](CS)C(=O)N[C@@H](CO)C(O)=O SPIPSJXLZVTXJL-ZLUOBGJFSA-N 0.000 claims 1
- REQUGIWGOGSOEZ-ZLUOBGJFSA-N Asn-Ser-Asn Chemical compound C([C@@H](C(=O)N[C@@H](CO)C(=O)N[C@@H](CC(=O)N)C(=O)O)N)C(=O)N REQUGIWGOGSOEZ-ZLUOBGJFSA-N 0.000 claims 1
- GZXOUBTUAUAVHD-ACZMJKKPSA-N Asn-Ser-Glu Chemical compound NC(=O)C[C@H](N)C(=O)N[C@@H](CO)C(=O)N[C@H](C(O)=O)CCC(O)=O GZXOUBTUAUAVHD-ACZMJKKPSA-N 0.000 claims 1
- QNIACYURSSCLRP-GUBZILKMSA-N Asp-Lys-Gln Chemical compound [H]N[C@@H](CC(O)=O)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCC(N)=O)C(O)=O QNIACYURSSCLRP-GUBZILKMSA-N 0.000 claims 1
- RONJIBWTGKVKFY-HTUGSXCWSA-N Gln-Thr-Phe Chemical compound C[C@H]([C@@H](C(=O)N[C@@H](CC1=CC=CC=C1)C(=O)O)NC(=O)[C@H](CCC(=O)N)N)O RONJIBWTGKVKFY-HTUGSXCWSA-N 0.000 claims 1
- NSVOVKWEKGEOQB-LURJTMIESA-N Gly-Pro-Gly Chemical compound NCC(=O)N1CCC[C@H]1C(=O)NCC(O)=O NSVOVKWEKGEOQB-LURJTMIESA-N 0.000 claims 1
- UIQGJYUEQDOODF-KWQFWETISA-N Gly-Tyr-Ala Chemical compound OC(=O)[C@H](C)NC(=O)[C@@H](NC(=O)CN)CC1=CC=C(O)C=C1 UIQGJYUEQDOODF-KWQFWETISA-N 0.000 claims 1
- UYODHPPSCXBNCS-XUXIUFHCSA-N Ile-Val-Leu Chemical compound CC[C@H](C)[C@H](N)C(=O)N[C@@H](C(C)C)C(=O)N[C@H](C(O)=O)CC(C)C UYODHPPSCXBNCS-XUXIUFHCSA-N 0.000 claims 1
- HVHRPWQEQHIQJF-AVGNSLFASA-N Leu-Lys-Glu Chemical compound [H]N[C@@H](CC(C)C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCC(O)=O)C(O)=O HVHRPWQEQHIQJF-AVGNSLFASA-N 0.000 claims 1
- MVVSHHJKJRZVNY-ACRUOGEOSA-N Leu-Phe-Tyr Chemical compound [H]N[C@@H](CC(C)C)C(=O)N[C@@H](CC1=CC=CC=C1)C(=O)N[C@@H](CC1=CC=C(O)C=C1)C(O)=O MVVSHHJKJRZVNY-ACRUOGEOSA-N 0.000 claims 1
- ZEDVFJPQNNBMST-CYDGBPFRSA-N Met-Arg-Ile Chemical compound [H]N[C@@H](CCSC)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H]([C@@H](C)CC)C(O)=O ZEDVFJPQNNBMST-CYDGBPFRSA-N 0.000 claims 1
- DRXODWRPPUFIAY-DCAQKATOSA-N Met-Asn-Lys Chemical compound CSCC[C@H](N)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@H](C(O)=O)CCCCN DRXODWRPPUFIAY-DCAQKATOSA-N 0.000 claims 1
- HTKNPQZCMLBOTQ-XVSYOHENSA-N Phe-Asn-Thr Chemical compound C[C@H]([C@@H](C(=O)O)NC(=O)[C@H](CC(=O)N)NC(=O)[C@H](CC1=CC=CC=C1)N)O HTKNPQZCMLBOTQ-XVSYOHENSA-N 0.000 claims 1
- GDUZTEQRAOXYJS-SRVKXCTJSA-N Ser-Phe-Asn Chemical compound C1=CC=C(C=C1)C[C@@H](C(=O)N[C@@H](CC(=O)N)C(=O)O)NC(=O)[C@H](CO)N GDUZTEQRAOXYJS-SRVKXCTJSA-N 0.000 claims 1
- GZYNMZQXFRWDFH-YTWAJWBKSA-N Thr-Arg-Pro Chemical compound C[C@H]([C@@H](C(=O)N[C@@H](CCCN=C(N)N)C(=O)N1CCC[C@@H]1C(=O)O)N)O GZYNMZQXFRWDFH-YTWAJWBKSA-N 0.000 claims 1
- SWIKDOUVROTZCW-GCJQMDKQSA-N Thr-Asn-Ala Chemical compound C[C@H]([C@@H](C(=O)N[C@@H](CC(=O)N)C(=O)N[C@@H](C)C(=O)O)N)O SWIKDOUVROTZCW-GCJQMDKQSA-N 0.000 claims 1
- YLXAMFZYJTZXFH-OLHMAJIHSA-N Thr-Asn-Asp Chemical compound C[C@H]([C@@H](C(=O)N[C@@H](CC(=O)N)C(=O)N[C@@H](CC(=O)O)C(=O)O)N)O YLXAMFZYJTZXFH-OLHMAJIHSA-N 0.000 claims 1
- VGYVVSQFSSKZRJ-OEAJRASXSA-N Thr-Phe-Lys Chemical compound NCCCC[C@@H](C(O)=O)NC(=O)[C@@H](NC(=O)[C@@H](N)[C@H](O)C)CC1=CC=CC=C1 VGYVVSQFSSKZRJ-OEAJRASXSA-N 0.000 claims 1
- VBMOVTMNHWPZJR-SUSMZKCASA-N Thr-Thr-Glu Chemical compound [H]N[C@@H]([C@@H](C)O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCC(O)=O)C(O)=O VBMOVTMNHWPZJR-SUSMZKCASA-N 0.000 claims 1
- COYHRQWNJDJCNA-NUJDXYNKSA-N Thr-Thr-Thr Chemical compound C[C@@H](O)[C@H](N)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H]([C@@H](C)O)C(O)=O COYHRQWNJDJCNA-NUJDXYNKSA-N 0.000 claims 1
- NOXKHHXSHQFSGJ-FQPOAREZSA-N Tyr-Ala-Thr Chemical compound C[C@@H](O)[C@@H](C(O)=O)NC(=O)[C@H](C)NC(=O)[C@@H](N)CC1=CC=C(O)C=C1 NOXKHHXSHQFSGJ-FQPOAREZSA-N 0.000 claims 1
- HVPPEXXUDXAPOM-MGHWNKPDSA-N Tyr-Ile-Leu Chemical compound CC(C)C[C@@H](C(O)=O)NC(=O)[C@H]([C@@H](C)CC)NC(=O)[C@@H](N)CC1=CC=C(O)C=C1 HVPPEXXUDXAPOM-MGHWNKPDSA-N 0.000 claims 1
- 230000036436 anti-hiv Effects 0.000 claims 1
- FSXRLASFHBWESK-UHFFFAOYSA-N dipeptide phenylalanyl-tyrosine Natural products C=1C=C(O)C=CC=1CC(C(O)=O)NC(=O)C(N)CC1=CC=CC=C1 FSXRLASFHBWESK-UHFFFAOYSA-N 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 108010078144 glutaminyl-glycine Proteins 0.000 claims 1
- 108010010147 glycylglutamine Proteins 0.000 claims 1
- 230000003053 immunization Effects 0.000 claims 1
- 238000002347 injection Methods 0.000 claims 1
- 239000007924 injection Substances 0.000 claims 1
- 108010009298 lysylglutamic acid Proteins 0.000 claims 1
- 102000039446 nucleic acids Human genes 0.000 claims 1
- 108020004707 nucleic acids Proteins 0.000 claims 1
- 210000002966 serum Anatomy 0.000 claims 1
- 108010071207 serylmethionine Proteins 0.000 claims 1
- 108010061238 threonyl-glycine Proteins 0.000 claims 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
- A61K39/21—Retroviridae, e.g. equine infectious anemia virus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/53—DNA (RNA) vaccination
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55566—Emulsions, e.g. Freund's adjuvant, MF59
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
- A61K2039/575—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2 humoral response
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2740/00—Reverse transcribing RNA viruses
- C12N2740/00011—Details
- C12N2740/10011—Retroviridae
- C12N2740/16011—Human Immunodeficiency Virus, HIV
- C12N2740/16051—Methods of production or purification of viral material
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2740/00—Reverse transcribing RNA viruses
- C12N2740/00011—Details
- C12N2740/10011—Retroviridae
- C12N2740/16011—Human Immunodeficiency Virus, HIV
- C12N2740/16111—Human Immunodeficiency Virus, HIV concerning HIV env
- C12N2740/16122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2740/00—Reverse transcribing RNA viruses
- C12N2740/00011—Details
- C12N2740/10011—Retroviridae
- C12N2740/16011—Human Immunodeficiency Virus, HIV
- C12N2740/16111—Human Immunodeficiency Virus, HIV concerning HIV env
- C12N2740/16134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2740/00—Reverse transcribing RNA viruses
- C12N2740/00011—Details
- C12N2740/10011—Retroviridae
- C12N2740/16011—Human Immunodeficiency Virus, HIV
- C12N2740/16111—Human Immunodeficiency Virus, HIV concerning HIV env
- C12N2740/16171—Demonstrated in vivo effect
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Virology (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Immunology (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Microbiology (AREA)
- Genetics & Genomics (AREA)
- Epidemiology (AREA)
- Mycology (AREA)
- Biochemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Communicable Diseases (AREA)
- Molecular Biology (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Gastroenterology & Hepatology (AREA)
- Hematology (AREA)
- Biophysics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Biomedical Technology (AREA)
- Biotechnology (AREA)
- General Engineering & Computer Science (AREA)
- AIDS & HIV (AREA)
- Tropical Medicine & Parasitology (AREA)
- Oncology (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Claims (15)
1. HIV gp140 trimer koji obuhvaća HIV gp140 polipeptid koji sadrži sekvencu aminokiselina najmanje 95% identično sekvenci:
[image]
[image]
sadrži trimerizacijsku domenu, i
peptid promjenjive petlje V3;
gdje HIV gp140 trimer trimer može izazvati proizvodnju neutralizacijskih antiseruma protiv HIV - a kada se stabilizirani trimer daje subjektu.
2. HIV gp140 trimer, sukladno patentnom zahtjevu 1, koji sadrži peptid promjenjive petlje V3 koji se sastoji od sekvence Thr Arg Pro Asn Asn Thn Arg Lys Ser Met Arg Ile Gly Pro Gly Gln Thr Phe Tyr Ala Thr Gly Asp Ile Gly Asp Ile Arg Gln Ala Tyr (SEQ ID N0: 8);
3. HIV gp 140 trimer sukladno zahtjevima 1 ili 2, gdje je trimerizacijska domena T4-fibritin fold trimerizacijska domena.
4. HIV gp 140 trimer, sukladno bilo kojem od prethodno navedenih zahtjeva 1 do 3, gdje
HIV gp140 polipeptid uključujuje promjenjive petlje peptida V1 i V2,
navedena V1 petlja peptid sastavljena od sekvenci Thr Asn Ala Thr Phe Lys Asn Asn Val Thr Asn Asp Met Asn Lys Glu Ile Arg Asn Cys Ser Phe Asn Thr Thr Thr Glu Ile Arg (SEQ ID NO: 4); i
navedena V2 petlja peptid sastavljena od sekvenci Ser Phe Asn Thr Thr Thr Glu Ile Arg Asp Lys Gln Gln Gly Tyr Ala Leu Phe Tyr Arg Pro Asp Ile Val Leu Leu Lys Glu Asn Arg Asn Asn Ser Asn Asn Ser Glu Tyr Ile Leu Ile Asn (SEQ ID NO: 6).
5. HIV gp 140 trimer, sukladno bilo kojem od prethodno navedenih zahtjeva 1 do 4, gdje HIV gp140 polipeptid obuhvaća sekvencu aminokiselina
[image]
[image]
6. HIV gp 140 trimer, sukladno bilo kojem od prethodno navedenih zahtjeva 1 do 5, gdje HIV je HIV-1
7. HIV gp 140 trimer sukladno zahtjevim 1 – 6, gdje neutralizirajući anti-HIV antiserum neutralizira HIV-1, odabranu izmedju jednog ili više Clade A, Clade B ili Clade C.
8. Farmaceutski spoj sadrži HIV gp 140 trimer, kao što je naznačenu u zahtjevima 1 - 7.
9. HIV gp 140 trimer, sukladno zahtjevima 1 – 7, ili farmaceutski spoj, sukladno zahtjevu 8. za korištenje kao cjepiva.
10. Cjepivo sadrži HIV gp 140 trimer sukladno patentnim zahtjevima 1 – 7.
11. Cjepivo sadrži sekvence nukleinske kiseline koja kodira HIV gp 140 trimer sukladno zahtjevima 1 – 7.
12. HIV gp 140 trimer sukladno patentnim zahtjevima 1 – 7 ili farmaceutski spoj sukladno patentnom zahtjevu 8, ili cjepivo sukladno patentnim zahtjevima 10 ili 11, naznačeni time, što se koristi kao postupak za proizvodnju neutralizirajućih seruma protiv HIV-a nakon injektiranja u subjekta.
13. HIV gp 140 trimer, sukladno patentnim zahtjevima 1- 7, ili farmaceuski spoj sukladno zahtjevu 8, ili cjepivo sukladno patentnim zahtjevima 10 ili 11, za uporabu za imunizaciju subjekta protiv HIV-a.
14. Postupak dobivanja HIV gp 140 trimera sukladno bilo kojem od zahtjeva 1 – 7, gdje postupak uključuje ekspresiju u eukariotskoj stanici domaćina vektora koji sadrži polipeptid i sadrži nukleinsku kiselinu koja enkodira sekvencu odgovarajućeg HIV gp 140 polipeptida.
15. Postupak dobivanja farmaceutskog spoja ili cjepiva koje sadrže HIV gp 140 trimer, spomenuti postupak sadrži postupak proizvodnje spomenutog HIV gp 140 trimera sukladno patentnom zahtjevu 14, i uključuje dobiveni HIV gp 140 trimer u farmaceutski spoj ili cjepivo sastavljeno od farmacutski prihvatljivog nossča.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US10444908P | 2008-10-10 | 2008-10-10 | |
EP18150843.3A EP3335728B8 (en) | 2008-10-10 | 2009-10-13 | Biochemically stabilized hiv-1 env trimer vaccine |
Publications (1)
Publication Number | Publication Date |
---|---|
HRP20200370T1 true HRP20200370T1 (hr) | 2020-06-12 |
Family
ID=42101262
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
HRP20180281TT HRP20180281T1 (hr) | 2008-10-10 | 2018-02-15 | Biokemijski stabilizirano hiv-1 env trimer cjepivo |
HRP20200370TT HRP20200370T1 (hr) | 2008-10-10 | 2020-03-04 | Biokemijski stabilizirano hiv-1 trimer cjepivo |
Family Applications Before (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
HRP20180281TT HRP20180281T1 (hr) | 2008-10-10 | 2018-02-15 | Biokemijski stabilizirano hiv-1 env trimer cjepivo |
Country Status (14)
Country | Link |
---|---|
US (6) | US9707289B2 (hr) |
EP (2) | EP2340038B1 (hr) |
AU (1) | AU2009303284B2 (hr) |
CY (2) | CY1119921T1 (hr) |
DK (2) | DK2340038T3 (hr) |
ES (2) | ES2659875T3 (hr) |
HR (2) | HRP20180281T1 (hr) |
HU (2) | HUE037270T2 (hr) |
LT (2) | LT2340038T (hr) |
PL (2) | PL2340038T3 (hr) |
PT (2) | PT2340038T (hr) |
SI (2) | SI2340038T1 (hr) |
TR (1) | TR201802130T4 (hr) |
WO (1) | WO2010042942A2 (hr) |
Families Citing this family (28)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20100028415A1 (en) | 2005-04-12 | 2010-02-04 | Haynes Barton F | Method of Inducing Neutralizing Antibodies to Human Immunodeficiency Virus |
CA2683752A1 (en) | 2007-04-13 | 2008-10-23 | Duke University | Method of inducing neutralizing antibodies to human immunodeficiency virus |
US20120070488A1 (en) * | 2007-09-28 | 2012-03-22 | Duke University | Method of inducing neutralizing antibodies to human immunodeficiency virus |
PT2340038T (pt) | 2008-10-10 | 2018-02-21 | Beth Israel Deaconess Medical Ct Inc | Vacina de trímero de envelope para hiv-1 bioquimicamente estabilizada |
JP2013505201A (ja) | 2009-04-03 | 2013-02-14 | デューク ユニバーシティー | 広域反応性中和抗hiv抗体を誘導するための配合物 |
US9060984B2 (en) * | 2010-10-30 | 2015-06-23 | George Dacai Liu | Recombinant HIV-1 envelope proteins comprising stabilizing two-cysteine mini-domains in gp41 |
WO2014022475A2 (en) * | 2012-08-03 | 2014-02-06 | Dana-Faber Cancer Institute, Inc. | Compositions and methods for conformationally stabilizing primate immunodeficiency virus envelope glycoprotein trimers |
AU2014203886B2 (en) * | 2013-01-07 | 2017-11-02 | Beth Israel Deaconess Medical Center, Inc. | Stabilized human immunodeficiency virus (HIV) envelope (Env) trimer vaccines and methods of using the same |
WO2014134547A1 (en) | 2013-02-28 | 2014-09-04 | Therabiol, Inc. | Hiv antigens and antibodies |
WO2014151687A2 (en) * | 2013-03-15 | 2014-09-25 | University Of Massachusetts | Compositions and methods to treat aids |
WO2015048635A1 (en) | 2013-09-27 | 2015-04-02 | Duke University | Mper-liposome conjugates and uses thereof |
US10716845B2 (en) | 2013-10-04 | 2020-07-21 | Beth Israel Deaconess Medical Center, Inc. | Stabilized human immunodeficiency virus (HIV) clade C envelope (Env) trimer vaccines and methods of using same |
PT3166607T (pt) | 2014-07-11 | 2022-12-07 | Gilead Sciences Inc | Moduladores de receptores de tipo toll para o tratamento do vih |
DK3197489T3 (da) * | 2014-09-26 | 2021-04-19 | Beth Israel Deaconess Medical Ct Inc | Fremgangsmåder og sammensætninger til at fremkalde beskyttende immunitet over for human immundefekt virusinfektion |
WO2016196471A1 (en) | 2015-06-02 | 2016-12-08 | Cooper Human Systems Llc | Methods and compositions for treatment of hiv infection |
HUE055916T2 (hu) | 2015-12-15 | 2021-12-28 | Janssen Vaccines & Prevention Bv | Emberi immunhiány vírus antigének, vektorok, készítmények és alkalmazásukra szóló eljárások |
EP3471765B1 (en) | 2016-06-16 | 2024-04-24 | Janssen Vaccines & Prevention B.V. | Hiv vaccine formulation |
CN110494159A (zh) | 2016-09-02 | 2019-11-22 | 扬森疫苗与预防公司 | 在接受抗逆转录病毒治疗的对象中诱导针对人类免疫缺陷病毒感染的免疫应答的方法 |
CA3036959A1 (en) | 2016-09-15 | 2018-03-22 | Janssen Vaccines & Prevention B.V. | Trimer stabilizing hiv envelope protein mutations |
WO2018075559A1 (en) | 2016-10-17 | 2018-04-26 | Beth Israel Deaconess Medical Center, Inc. | Signature-based human immunodeficiency virus (hiv) envelope (env) trimer vaccines and methods of using the same |
CN110958887B (zh) | 2017-06-15 | 2023-10-31 | 扬森疫苗与预防公司 | 编码hiv抗原的痘病毒载体及其使用方法 |
WO2019016062A1 (en) | 2017-07-19 | 2019-01-24 | Janssen Vaccines & Prevention B.V. | HIV ENVELOPE PROTEIN MUTATIONS STABILIZING TRIMERIC FORM |
WO2019018724A1 (en) | 2017-07-21 | 2019-01-24 | Janssen Vaccines & Prevention B.V. | METHODS FOR SAFE INDUCTION OF MULTICLADED CROSS-IMMUNITY AGAINST HUMAN IMMUNODEFICIENCY VIRUS INFECTION IN HUMAN BEINGS |
WO2019055888A1 (en) | 2017-09-18 | 2019-03-21 | Janssen Vaccines & Prevention B.V. | METHODS OF INDUCING AN IMMUNE RESPONSE AGAINST HUMAN IMMUNODEFICIENCY VIRUS INFECTION IN SUBJECTS UNDER ANTIRETROVIRAL TREATMENT |
AU2019345942A1 (en) | 2018-09-25 | 2021-03-18 | Janssen Vaccines & Prevention B.V. | Method of inducing an immune response against human immunodeficiency virus by co-localized administration of vaccine components |
WO2020237052A1 (en) | 2019-05-22 | 2020-11-26 | Janssen Vaccines & Prevention B.V. | Methods for inducing an immune response against human immunodeficiency virus infection in subjects undergoing antiretroviral treatment |
WO2021089770A2 (en) | 2019-11-07 | 2021-05-14 | Janssen Vaccines & Prevention B.V. | Protein purification |
WO2023198815A1 (en) | 2022-04-14 | 2023-10-19 | Janssen Vaccines & Prevention B.V. | Sequential administration of adenoviruses |
Family Cites Families (48)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4603112A (en) | 1981-12-24 | 1986-07-29 | Health Research, Incorporated | Modified vaccinia virus |
US4522811A (en) | 1982-07-08 | 1985-06-11 | Syntex (U.S.A.) Inc. | Serial injection of muramyldipeptides and liposomes enhances the anti-infective activity of muramyldipeptides |
US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
JPS6147500A (ja) | 1984-08-15 | 1986-03-07 | Res Dev Corp Of Japan | キメラモノクロ−ナル抗体及びその製造法 |
EP0173494A3 (en) | 1984-08-27 | 1987-11-25 | The Board Of Trustees Of The Leland Stanford Junior University | Chimeric receptors by dna splicing and expression |
GB8422238D0 (en) | 1984-09-03 | 1984-10-10 | Neuberger M S | Chimeric proteins |
JPS61134325A (ja) | 1984-12-04 | 1986-06-21 | Teijin Ltd | ハイブリツド抗体遺伝子の発現方法 |
US5225539A (en) | 1986-03-27 | 1993-07-06 | Medical Research Council | Recombinant altered antibodies and methods of making altered antibodies |
DE122007000007I2 (de) | 1986-04-09 | 2010-12-30 | Genzyme Corp | Genetisch transformierte Tiere, die ein gewünschtes Protein in Milch absondern |
US4873316A (en) | 1987-06-23 | 1989-10-10 | Biogen, Inc. | Isolation of exogenous recombinant proteins from the milk of transgenic mammals |
US5223409A (en) | 1988-09-02 | 1993-06-29 | Protein Engineering Corp. | Directed evolution of novel binding proteins |
DE768377T1 (de) | 1988-09-02 | 1998-01-02 | Dyax Corp | Herstellung und Auswahl von Rekombinantproteinen mit verschiedenen Bindestellen |
US5298416A (en) | 1989-01-18 | 1994-03-29 | British Technology Group Ltd. | Attenuated polioviruses |
US5328470A (en) | 1989-03-31 | 1994-07-12 | The Regents Of The University Of Michigan | Treatment of diseases by site-specific instillation of cells or site-specific transformation of cells and kits therefor |
US5427908A (en) | 1990-05-01 | 1995-06-27 | Affymax Technologies N.V. | Recombinant library screening methods |
ES2139598T3 (es) | 1990-07-10 | 2000-02-16 | Medical Res Council | Procedimientos para la produccion de miembros de parejas de union especifica. |
GB9015198D0 (en) | 1990-07-10 | 1990-08-29 | Brien Caroline J O | Binding substance |
DE69129154T2 (de) | 1990-12-03 | 1998-08-20 | Genentech Inc | Verfahren zur anreicherung von proteinvarianten mit geänderten bindungseigenschaften |
EP1820858B1 (en) | 1991-03-01 | 2009-08-12 | Dyax Corporation | Chimeric protein comprising micro-protein having two or more disulfide bonds and embodiments thereof |
ES2315612T3 (es) | 1991-04-10 | 2009-04-01 | The Scripps Research Institute | Genotecas de receptores heterodimericos usando fagemidos. |
DE4122599C2 (de) | 1991-07-08 | 1993-11-11 | Deutsches Krebsforsch | Phagemid zum Screenen von Antikörpern |
US5505947A (en) | 1994-05-27 | 1996-04-09 | The University Of North Carolina At Chapel Hill | Attenuating mutations in Venezuelan Equine Encephalitis virus |
US6710173B1 (en) | 1999-06-25 | 2004-03-23 | Progenics Pharmaceuticals, Inc. | Stabilized viral envelope proteins and uses thereof |
WO2001019958A2 (en) * | 1999-09-17 | 2001-03-22 | Dana-Farber Cancer Institute, Inc. | Stabilized soluble glycoprotein trimers |
WO2004044155A2 (en) | 2002-11-07 | 2004-05-27 | Beth Israel Deaconess Medical Center | MIP-1α AND GM-CSF AS ADJUVANTS OF IMMUNE RESPONSE |
EP1578766B1 (en) * | 2002-12-03 | 2013-02-13 | University of Massachusetts | Polyvalent, primary hiv-1 glycoprotein dna vaccines and vaccination methods |
US20070298051A1 (en) | 2003-11-19 | 2007-12-27 | Beth Israel Deaconess Medical Center | Adjuvants Of Immune Response |
EP1766097A4 (en) * | 2004-06-15 | 2008-03-19 | Progenics Pharm Inc | HIV-1 NEUTRALIZATION ANTIBODIES ELICITED BY A TRIMERIC COMPLEX OF HIV-1 ENVELOPE GLYCOPROTEINS |
ATE527281T1 (de) * | 2004-07-16 | 2011-10-15 | Us Gov Health & Human Serv | Impfstoffe gegen aids umfassend cmv/r nucleinsäurekonstrukte |
WO2006040330A2 (en) | 2004-10-13 | 2006-04-20 | Crucell Holland B.V. | Improved adenoviral vectors and uses thereof |
US20100221241A1 (en) * | 2005-07-06 | 2010-09-02 | University Of Maryland Biotechnology Institute | Constrained hiv envelope-based immunogen that simultaneously presents receptor and coreceptor binding sites |
AU2006283101B2 (en) | 2005-08-23 | 2013-03-07 | Beth Israel Deaconess Medical Center | Polyvalent vaccine |
US20100143302A1 (en) | 2006-03-16 | 2010-06-10 | Crucell Holland B.V. | Recombinant Adenoviruses Based on Serotype 26 and 48, and Use Thereof |
US20110076298A1 (en) | 2006-06-19 | 2011-03-31 | Olson William C | Soluble stabilized trimeric hiv env proteins and uses thereof |
EP2073840A4 (en) | 2006-10-23 | 2010-10-27 | Progenics Pharm Inc | MODIFIED GP140 ENVELOPE POLYPEPTIDES FROM HIV-1 ISOLATES, COMPOSITIONS, TRIMERIC COMPLEXES AND USES THEREOF |
PT2340038T (pt) | 2008-10-10 | 2018-02-21 | Beth Israel Deaconess Medical Ct Inc | Vacina de trímero de envelope para hiv-1 bioquimicamente estabilizada |
SI2358757T1 (sl) | 2008-11-18 | 2018-12-31 | Beth Israel Deaconess Medical Center | Antivirusna cepiva z izboljšano celularno imunogenostjo |
IT1395574B1 (it) | 2009-09-14 | 2012-10-16 | Guala Dispensing Spa | Dispositivo di erogazione |
SI3556396T1 (sl) | 2010-08-31 | 2022-09-30 | Theraclone Sciences, Inc. | Nevtralizacijska protitelesa proti virusu človeške imunske pomanjkljivosti (HIV) |
WO2013036791A2 (en) | 2011-09-09 | 2013-03-14 | Beth Israel Deaconess Medical Center, Inc. | Modified adenoviral vectors and methods of treatment using same |
AU2012216792A1 (en) | 2011-09-12 | 2013-03-28 | International Aids Vaccine Initiative | Immunoselection of recombinant vesicular stomatitis virus expressing HIV-1 proteins by broadly neutralizing antibodies |
EP2766037A4 (en) | 2011-10-12 | 2015-08-05 | Scripps Research Inst | HIV-1 GP-120 MINI-V3 LOOP AND USES THEREOF |
US9683268B2 (en) | 2012-09-19 | 2017-06-20 | Beth Israel Deaconess | Viruses associated with immunodeficiency and enteropathy and methods using same |
CA3200425A1 (en) | 2012-11-16 | 2014-05-22 | Peter ABBINK | Recombinant adenoviruses and use thereof |
AU2014203886B2 (en) | 2013-01-07 | 2017-11-02 | Beth Israel Deaconess Medical Center, Inc. | Stabilized human immunodeficiency virus (HIV) envelope (Env) trimer vaccines and methods of using the same |
WO2015004158A1 (en) * | 2013-07-08 | 2015-01-15 | Novartis Ag | Rotavirus particles with chimeric surface proteins |
WO2015048770A2 (en) | 2013-09-30 | 2015-04-02 | Beth Israel Deaconess Medical Center, Inc. | Antibody therapies for human immunodeficiency virus (hiv) |
US10444908B2 (en) | 2016-12-31 | 2019-10-15 | Innoventions, Inc. | Virtual touchpads for wearable and portable devices |
-
2009
- 2009-10-13 PT PT98200447T patent/PT2340038T/pt unknown
- 2009-10-13 PL PL09820044T patent/PL2340038T3/pl unknown
- 2009-10-13 HU HUE09820044A patent/HUE037270T2/hu unknown
- 2009-10-13 TR TR2018/02130T patent/TR201802130T4/tr unknown
- 2009-10-13 PT PT181508433T patent/PT3335728T/pt unknown
- 2009-10-13 PL PL18150843T patent/PL3335728T3/pl unknown
- 2009-10-13 LT LTEP09820044.7T patent/LT2340038T/lt unknown
- 2009-10-13 HU HUE18150843A patent/HUE049393T2/hu unknown
- 2009-10-13 ES ES09820044.7T patent/ES2659875T3/es active Active
- 2009-10-13 EP EP09820044.7A patent/EP2340038B1/en active Active
- 2009-10-13 SI SI200931800T patent/SI2340038T1/en unknown
- 2009-10-13 EP EP18150843.3A patent/EP3335728B8/en active Active
- 2009-10-13 LT LTEP18150843.3T patent/LT3335728T/lt unknown
- 2009-10-13 ES ES18150843T patent/ES2765890T3/es active Active
- 2009-10-13 AU AU2009303284A patent/AU2009303284B2/en not_active Ceased
- 2009-10-13 SI SI200932027T patent/SI3335728T1/sl unknown
- 2009-10-13 DK DK09820044.7T patent/DK2340038T3/en active
- 2009-10-13 WO PCT/US2009/060494 patent/WO2010042942A2/en active Application Filing
- 2009-10-13 DK DK18150843.3T patent/DK3335728T3/da active
-
2011
- 2011-04-08 US US13/082,601 patent/US9707289B2/en active Active
-
2017
- 2017-05-16 US US15/596,312 patent/US9950060B2/en active Active
-
2018
- 2018-02-15 HR HRP20180281TT patent/HRP20180281T1/hr unknown
- 2018-02-15 CY CY20181100190T patent/CY1119921T1/el unknown
- 2018-03-13 US US15/919,834 patent/US10307478B2/en active Active
-
2019
- 2019-04-16 US US16/385,438 patent/US10463729B2/en not_active Expired - Fee Related
- 2019-09-23 US US16/579,025 patent/US10653770B2/en active Active
-
2020
- 2020-01-23 CY CY20201100062T patent/CY1122745T1/el unknown
- 2020-03-04 HR HRP20200370TT patent/HRP20200370T1/hr unknown
- 2020-04-27 US US16/858,808 patent/US11229696B2/en active Active
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
HRP20200370T1 (hr) | Biokemijski stabilizirano hiv-1 trimer cjepivo | |
KR102638978B1 (ko) | Rsv에 대한 백신 | |
CN107022008B (zh) | 广谱地抑制人类冠状病毒感染的多肽及其应用 | |
IL278014B2 (en) | Anti-myostatin antibodies, polypeptides containing variable FC regions and methods of use | |
HRP20140109T1 (hr) | Novi imunoadjuvantni spojevi na bazi flagelina i njihova upotreba | |
AU2021232702B2 (en) | Stabilized pre-fusion RSV F proteins | |
EA035909B1 (ru) | Стабилизированные растворимые f-полипептиды rsv до слияния | |
RU2015103816A (ru) | ПРОНИКАЮЩИЕ В КЛЕТКУ ПЕПТИДЫ, МИШЕНЬЮ КОТОРЫХ ЯВЛЯЕТСЯ eIF4E | |
KR20150023735A (ko) | 안정화된 gp120 | |
WO2017207477A1 (en) | Stabilized pre-fusion rsv f proteins | |
EA201100459A1 (ru) | Композиции, включающие интерлейкин-1 и пептиды | |
CN113227123A (zh) | 重组呼吸道合胞病毒f蛋白以及包含该蛋白的疫苗组合物 | |
RU2009115688A (ru) | Иммуногенные гибридные полипептиды против ожирения и композиция вакцин против ожирения, содержащая эти полипептиды | |
WO2005002500A2 (en) | Inhibitors of coronavirus | |
CN117126292A (zh) | 痘病毒重组嵌合抗原、包含其的免疫原性组合物及其应用 | |
WO2012050893A3 (en) | Immunogenic polypeptides having an immunogenic scaffold protein and a loop peptide, presenting a 3074- or 2219/2557- monoclonal antibody-targeted epitope, which is present in the hiv gp120 protein | |
EA201190097A1 (ru) | РАСЩЕПЛЕНИЕ gp41 | |
Crane et al. | Identification of the fusion domain in the visna virus transmembrane protein | |
AU2015226580B2 (en) | Beta-hairpin peptides having anti-viral properties against the dengue virus | |
CN101838318B (zh) | 抗hiv-i的多肽、其编码序列及其用途 | |
RU2020122924A (ru) | Пептидные иммуногены il-31 и их составы для лечения и/или профилактики атопического дерматита | |
RU2021100733A (ru) | Неоантигены и их применение | |
OA19273A (en) | Stabilized pre-fusion RSV F proteins. | |
US20140079735A1 (en) | Antibody recognizing arbitrarily designed epitope of three or more amino acid residues in a peptide and method of generating thereof | |
CN101899100A (zh) | 抗hiv-i的多肽、其编码序列及其用途 |